MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.2 USD | +0.37% |
|
+4.31% | +20.34% |
| 05:51pm | Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 | MT |
| 05:05pm | Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 | MT |
Financials (USD)
| Sales 2024 * | 63.97B | Sales 2025 * | 68.29B | Capitalization | 331B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.09B | Net income 2025 * | 21.78B | EV / Sales 2024 * | 5.47 x |
| Net Debt 2024 * | 18.78B | Net Debt 2025 * | 7.97B | EV / Sales 2025 * | 4.97 x |
| P/E ratio 2024 * |
16.9
x | P/E ratio 2025 * |
14.7
x | Employees | 71,000 |
| Yield 2024 * |
2.36% | Yield 2025 * |
2.47% | Free-Float | 70.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 day | +0.35% | ||
| 1 week | +4.26% | ||
| Current month | -0.61% | ||
| 1 month | +4.48% | ||
| 3 months | +8.54% | ||
| 6 months | +24.24% | ||
| Current year | +20.29% |
1 week
125.35
132.80
1 month
124.50133.10
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 215 M€ | +10.97% | - | |
| 5.61% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 131.2 | +0.37% | 7 757 175 |
| 24-04-25 | 130.7 | +2.93% | 12,750,052 |
| 24-04-24 | 127 | +0.09% | 7,128,300 |
| 24-04-23 | 126.9 | -0.05% | 7,743,961 |
| 24-04-22 | 126.9 | +0.92% | 7,805,992 |
Delayed Quote Nyse, April 26, 2024 at 11:51 am EDT
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.7
USD
Average target price
139.6
USD
Spread / Average Target
+6.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.29% | 331B | |
| +26.30% | 653B | |
| +27.00% | 556B | |
| -6.44% | 354B | |
| +3.76% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.17% | 144B | |
| -11.83% | 143B |
- Stock Market
- Equities
- MRK Stock
